Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy.
Radiother Oncol
; 142: 133-139, 2020 01.
Article
em En
| MEDLINE
| ID: mdl-31431373
ABSTRACT
PURPOSE:
We report longitudinal patient-reported quality-of-life (QoL) outcomes related to xerostomia in patients with oropharyngeal cancer treated with intensity-modulated proton therapy (IMPT). MATERIALS ANDMETHODS:
Patients treated from May 2012 through December 2016 at a single institution for AJCC7 stage III-IV, M0 oropharyngeal cancer were given the 15-item Xerostomia-Related QoL Scale (XeQoLS) before, during, and for up to 2â¯years after treatment. We evaluated the evolution of xerostomia-related QoL over that time, and examined potential associations between those measures with clinical characteristics.RESULTS:
Sixty-nine patients had XeQoLS scores at baseline and at least once either during or after treatment. The mean (±SD) XeQoLS score (0-4) was 0.24⯱â¯0.57 at baseline. Subsequent scores were 2.00⯱â¯1.01 at 6â¯weeks on treatment, and 1.03⯱â¯0.76, 0.97⯱â¯0.78, 0.82⯱â¯0.69, and 0.70⯱â¯0.75 at 10â¯weeks, 6â¯months, 1â¯year, and 2â¯years after treatment, respectively. All were statistically different from baseline (pâ¯<â¯0.001). Univariate analyses demonstrated associations between XeQoLS score and time (pâ¯<â¯0.0001 for each interval), baseline XeQoLS score (pâ¯<â¯0.0001), stage (pâ¯=â¯0.008), N status (pâ¯=â¯0.006), and mean oral cavity dose (pâ¯=â¯0.038), but not for age, sex, T status, receipt of chemotherapy, smoking history, disease site, laterality of neck irradiation, mean parotid dose, or mean submandibular dose. Multivariate analysis suggested that baseline XeQoLS scores, phase of treatment, and N status were associated with XeQoLS scores measured during treatment and recovery.CONCLUSIONS:
Patients receiving IMPT reported the greatest xerostomia-related QoL impairment at 6â¯weeks on treatment, with a 49% improvement by 10â¯weeks after treatment; however, XeQoLS scores remained above baseline after 2â¯years. As we aim to establish the value of IMPT in oropharyngeal tumors to de-intensify treatment over conventional therapy, these data help inform discussions about xerostomia-related quality of life for patients with oropharyngeal cancer treated with IMPT.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Lesões por Radiação
/
Xerostomia
/
Neoplasias Orofaríngeas
/
Terapia com Prótons
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article